Mineralization by mesenchymal stromal cells is variously modulated depending on commercial platelet lysate preparations

Boraldi, Federica; Burns, Jorge S.; Bartolomeo, Angelica; Dominici, Massimo; Quaglino, Daniela

doi:10.1016/j.jcyt.2017.11.011

Cited by 12 publications

(8 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This discrepancy persists when comparing the absolute results of alizarin red staining and ALP activity measurement: in alizarin red staining, the hPL groups showed calcium content higher than or as high as the FCS groups while ALP activity varies more, especially when comparing H1 and F10 groups, where the F10 group presents higher ALP activity throughout differentiation from day seven onwards. For the pairs of H1 vs. F1 and H10 vs. F10, the previously described statement of superiority or equality of the hPL [16,17,[21][22][23][24][26][27][28]31] is still valid.…”

Section: Discussionmentioning

confidence: 92%

“…Several studies evaluated BMSC differentiation potential after cell expansion in hPL-containing medium, while the differentiation medium itself contained only FCS as a supplement [17,18,22,23,[28][29][30]. There have also been multiple studies reporting that hPL does not affect osteogenic differentiation [16,17,21,22,24,[27][28][29]31] or even increases the osteogenic differentiation potential of BMSC [22,23,25,26]. However, it remains unclear how hPL as a part of an osteogenic differentiation medium (ODM) influences the kinetics of the osteogenic differentiation of BMSC.…”

Section: Introductionmentioning

confidence: 99%

“…However, it remains unclear how hPL as a part of an osteogenic differentiation medium (ODM) influences the kinetics of the osteogenic differentiation of BMSC. Furthermore, the necessary concentrations of hPL reported differ from 2% to 10% [18,20,25,26,[29][30][31][32][33][34], pointing out that there is no established standard protocol for hPL supplementation in ODM for BMSC yet, although the concentration of serum supplement in media resulting in different concentrations of growth factors and other components of the serum influences cells in culture [1].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Human Platelet Lysate Can Replace Fetal Calf Serum as a Protein Source to Promote Expansion and Osteogenic Differentiation of Human Bone-Marrow-Derived Mesenchymal Stromal Cells

Karadjian

Senger

Essers

et al. 2020

Cells

View full text Add to dashboard Cite

Fetal calf serum (FCS) is frequently used as a growth factor and protein source in bone-marrow-derived mesenchymal stromal cell (BMSC) culture media, although it is a xenogenic product presenting multiple disadvantages including but not limited to ethical concerns. A promising alternative for FCS is human platelet lysate (hPL), which is produced out of human platelet concentrates and happens to be a stable and reliable protein source. In this study, we investigated the influence of hPL in an expansion medium (ESM) and an osteogenic differentiation medium (ODM) on the proliferation and osteogenic differentiation capacity of human BMSC. Therefore, we assessed population doublings during cell expansion, performed alizarin red staining to evaluate the calcium content in the extracellular matrix and determined the activity of alkaline phosphatase (ALP) as osteogenic differentiation correlates. The proliferation rate of BMSC cultured in ESM supplemented with hPL exceeded the proliferation rate of BMSC cultured in the presence of FCS. Furthermore, the calcium content and ALP activity was significantly higher in samples incubated in hPL-supplemented ODM, especially in the early phases of differentiation. Our results show that hPL can replace FCS as a protein supplier in cell culture media and does not negatively affect the osteogenic differentiation capacity of BMSC.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Human Platelet Lysate Can Replace Fetal Calf Serum as a Protein Source to Promote Expansion and Osteogenic Differentiation of Human Bone-Marrow-Derived Mesenchymal Stromal Cells

Karadjian

Senger

Essers

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…Recent studies have reported differences in MSC proliferation and osteogenic differentiation when cultured in different HPL formulations, expressing differences in their protein compositions [ 15 , 73 ]. MSC proliferation, i.e., PD rate/time, is considered a “key parameter” during ex vivo expansion [ 11 ], and ALP and mineralization assays are routinely used to test the in vitro osteogenic capacity of MSCs.…”

Section: Discussionmentioning

confidence: 99%

“…In the context of BTE, a recent study demonstrated differential effects of commercial HPL products on the mineralization capacity of BMSCs, although the mechanisms and HPL components contributing to these differences were not studied [ 15 ]. It would be of interest to investigate the effects of PC storage times on the cytokine contents of HPL, and subsequently the proliferation kinetics and osteogenic differentiation potential of HPL-expanded MSCs.…”

Section: Introductionmentioning

confidence: 99%

Influence of platelet storage time on human platelet lysates and platelet lysate-expanded mesenchymal stromal cells for bone tissue engineering

et al. 2020

View full text Add to dashboard Cite

Background Human platelet lysate (HPL) is emerging as the preferred xeno-free supplement for the expansion of mesenchymal stromal cells (MSCs) for bone tissue engineering (BTE) applications. Due to a growing demand, the need for standardization and scaling-up of HPL has been highlighted. However, the optimal storage time of the source material, i.e., outdated platelet concentrates (PCs), remains to be determined. The present study aimed to determine the optimal storage time of PCs in terms of the cytokine content and biological efficacy of HPL. Methods Donor-matched bone marrow (BMSCs) and adipose-derived MSCs (ASCs) expanded in HPL or fetal bovine serum (FBS) were characterized based on in vitro proliferation, immunophenotype, and multi-lineage differentiation. Osteogenic differentiation was assessed at early (gene expression), intermediate [alkaline phosphatase (ALP) activity], and terminal stages (mineralization). Using a multiplex immunoassay, the cytokine contents of HPLs produced from PCs stored for 1–9 months were screened and a preliminary threshold of 4 months was identified. Next, HPLs were produced from PCs stored for controlled durations of 0, 1, 2, 3, and 4 months, and their efficacy was compared in terms of cytokine content and BMSCs’ proliferation and osteogenic differentiation. Results BMSCs and ASCs in both HPL and FBS demonstrated a characteristic immunophenotype and multi-lineage differentiation; osteogenic differentiation of BMSCs and ASCs was significantly enhanced in HPL vs. FBS. Multiplex network analysis of HPL revealed several interacting growth factors, chemokines, and inflammatory cytokines. Notably, stem cell growth factor (SCGF) was detected in high concentrations. A majority of cytokines were elevated in HPLs produced from PCs stored for ≤ 4 months vs. > 4 months. However, no further differences in PC storage times between 0 and 4 months were identified in terms of HPLs’ cytokine content or their effects on the proliferation, ALP activity, and mineralization of BMSCs from multiple donors. Conclusions MSCs expanded in HPL demonstrate enhanced osteogenic differentiation, albeit with considerable donor variation. HPLs produced from outdated PCs stored for up to 4 months efficiently supported the proliferation and osteogenic differentiation of MSCs. These findings may facilitate the standardization and scaling-up of HPL from outdated PCs for BTE applications.

show abstract

Bio-mineral Interactions and the Environment

Giudici

Medas

Meneghini

2023

Earth and Environmental Sciences Library

View full text Add to dashboard Cite

Mineralization by mesenchymal stromal cells is variously modulated depending on commercial platelet lysate preparations

Cited by 12 publications

References 43 publications

Human Platelet Lysate Can Replace Fetal Calf Serum as a Protein Source to Promote Expansion and Osteogenic Differentiation of Human Bone-Marrow-Derived Mesenchymal Stromal Cells

Human Platelet Lysate Can Replace Fetal Calf Serum as a Protein Source to Promote Expansion and Osteogenic Differentiation of Human Bone-Marrow-Derived Mesenchymal Stromal Cells

Influence of platelet storage time on human platelet lysates and platelet lysate-expanded mesenchymal stromal cells for bone tissue engineering

Bio-mineral Interactions and the Environment

Contact Info

Product

Resources

About